From the FDA Drug Label
The FDA drug label does not answer the question.
From the Research
The acronym EAGLE in the EAGLE trial stands for Evaluating Antibiotics in Genitourinary Infections: Gepotidacin Efficacy, as described in the study published in 2022 1. This clinical trial evaluated the effectiveness of gepotidacin, a novel oral antibiotic, for treating urinary tract infections (UTIs). The EAGLE trial specifically assessed gepotidacin's efficacy against various uropathogens, comparing it to nitrofurantoin, a commonly used antibiotic for UTIs.
The study design involved two phase III, randomized, multicenter trials (EAGLE-2 and EAGLE-3) that enrolled women aged 12 years and older with uncomplicated UTIs 1. The primary therapeutic endpoint was composite clinical and microbiological efficacy, with noninferiority comparisons made in individuals with a qualifying uropathogen.
Gepotidacin represents a potential treatment option for UTIs, particularly in an era of increasing antibiotic resistance 1. The EAGLE trial's findings have contributed to the current understanding of appropriate antibiotic selection and treatment duration for urinary tract infections.
Key points to consider when treating UTIs include:
- The rising concern of antibiotic resistance, as highlighted in a 2025 study 2
- The importance of antimicrobial stewardship and continuous surveillance of antimicrobial resistance patterns 2
- The efficacy of nitrofurantoin and fosfomycin as first-line options for uncomplicated UTIs 3, 2
- The need for evidence-based guidance for clinicians treating patients with UTIs, particularly in an era of increasing antibiotic resistance 1, 3, 2